Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 1
1954 1
1956 1
1958 2
1959 1
1962 2
1964 1
1968 1
1970 1
1972 1
1974 5
1975 2
1976 4
1977 1
1978 6
1979 2
1980 4
1981 8
1982 8
1983 6
1984 5
1985 5
1986 4
1987 7
1988 6
1989 4
1990 10
1991 7
1992 8
1993 7
1994 12
1995 17
1996 19
1997 18
1998 15
1999 22
2000 24
2001 36
2002 34
2003 30
2004 35
2005 26
2006 49
2007 58
2008 40
2009 65
2010 56
2011 71
2012 81
2013 99
2014 104
2015 93
2016 112
2017 118
2018 98
2019 84
2020 43
Text availability
Article attribute
Article type
Publication date

Search Results

1,413 results
Results by year
Filters applied: . Clear all
Page 1
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.
Cline EN, Bicca MA, Viola KL, Klein WL. Cline EN, et al. J Alzheimers Dis. 2018;64(s1):S567-S610. doi: 10.3233/JAD-179941. J Alzheimers Dis. 2018. PMID: 29843241 Free PMC article. Review.
However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied app …
However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful …
Interleukin-6 as a therapeutic target.
Rossi JF, Lu ZY, Jourdan M, Klein B. Rossi JF, et al. Clin Cancer Res. 2015 Mar 15;21(6):1248-57. doi: 10.1158/1078-0432.CCR-14-2291. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589616 Free article. Review.
In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. ...Interestingly, the inhibition of C-reactive protein (CRP) production is a trustworthy surrogate marker of anti-IL6 therapy efficacy. ...
In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. ...Inte …
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015.
Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, Goossens H, Laxminarayan R. Klein EY, et al. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470. doi: 10.1073/pnas.1717295115. Epub 2018 Mar 26. Proc Natl Acad Sci U S A. 2018. PMID: 29581252 Free PMC article.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
METHODS: Patients naive to biologic therapy with active PsA were randomised to subcutaneous injections of placebo (N=106), adalimumab 40 mg once every 2 weeks (active reference; N=101), ixekizumab 80 mg once every 2 weeks (IXEQ2W) (N=103), or ixekizumab 80 mg once every 4 …
METHODS: Patients naive to biologic therapy with active PsA were randomised to subcutaneous injections of placebo (N=106), adalimumab …
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT. Meder L, et al. Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18. Cancer Res. 2018. PMID: 29776963 Free article.
We show in an autochthonous mouse model of SCLC that combined anti-VEGF/anti-PD-L1-targeted therapy synergistically improves treatment outcome compared with anti-PD-L1 and anti-VEGF monotherapy. ...
We show in an autochthonous mouse model of SCLC that combined anti-VEGF/anti-PD-L1-targeted therapy synergistically improves treatmen …
Impact of sex and gender on COVID-19 outcomes in Europe.
Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Gebhard C, et al. Biol Sex Differ. 2020 May 25;11(1):29. doi: 10.1186/s13293-020-00304-9. Biol Sex Differ. 2020. PMID: 32450906 Free PMC article. Review.
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.
Ramos DM, d'Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, Matson J, Taylor SJ, Zaworski PG, Prior TW, Snyder PJ, Valdivia D, Hatem CL, Waters I, Gupte N, Swoboda KJ, Rigo F, Bennett CF, Naryshkin N, Paushkin S, Crawford TO, Sumner CJ. Ramos DM, et al. J Clin Invest. 2019 Nov 1;129(11):4817-4831. doi: 10.1172/JCI124120. J Clin Invest. 2019. PMID: 31589162 Free PMC article. Clinical Trial.
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators. Wadden TA, et al. Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1. Int J Obes (Lond). 2013. PMID: 23812094 Free article. Clinical Trial.
RESULTS: Participants (n=422) lost a mean 6.0% (s.d. 0.9) of screening weight during run-in. From randomization to week 56, weight decreased an additional mean 6.2% (s.d. 7.3) with liraglutide and 0.2% (s.d. 7.0) with placebo (estimated difference -6.1% (95% …
RESULTS: Participants (n=422) lost a mean 6.0% (s.d. 0.9) of screening weight during run-in. From randomization to week 56, weight de …
[Insulin therapy-new insulin analogues].
Ehren M, Klein HH. Ehren M, et al. Internist (Berl). 2019 Sep;60(9):887-894. doi: 10.1007/s00108-019-0652-1. Internist (Berl). 2019. PMID: 31396651 Review. German.
Sucralose affects glycemic and hormonal responses to an oral glucose load.
Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Pepino MY, et al. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30. Diabetes Care. 2013. PMID: 23633524 Free PMC article. Clinical Trial.
1,413 results
Jump to page
Feedback